Compare Gilead Sciences, Inc. (GILD) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs S&P500 ETF — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while S&P500 ETF trades at $754.19. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | SPY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $759.55 |
52-Week Low | $108.22 | $621.75 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SPY, the SPDR S&P 500 ETF, trades at $751.35, down 0.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF is positioned near key support at $751, with resistance at $757. Recent news highlights market concentration, rate cut hopes from soft CPI data, and analyst optimism for S&P 500 gains, with targets like 8,000 by year-end from Fundstrat's Tom Lee (CNBC, 2026-07-13).
The outlook for SPY remains positive amid broadening market performance and potential Fed easing, though risks include AI fatigue and high valuations. Earnings season could provide a catalyst, but investors face volatility from economic data and equity-bond correlations. The dividend of $1.90 payable July 31, 2026, adds income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
